SFA
CYTK icon

Sequoia Financial Advisors’s Cytokinetics CYTK Stock Holding History

Sequoia Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Buy
3,516
+124
+4% +$8.9K ﹤0.01% 1671
2026
Q1 		$224K Buy
+3,392
New +$216K ﹤0.01% 1734
2024
Q1 		– Sell
-3,147
Closed -$263K – 1194
2023
Q4 		$263K Buy
+3,147
New +$114K ﹤0.01% 985

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sequoia Financial Advisors's CYTK Position: Q2 2026 in Review

Sequoia Financial Advisors increased its Cytokinetics (CYTK) stake by 3.7% in Q2 2026, buying an estimated $8.9K and bringing the position to 3,516 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #1671.

Sequoia Financial Advisors first reported a position in CYTK in Q4 2023 and has held it in 3 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Sequoia Financial Advisors held 3,516 shares of Cytokinetics worth $300K as of Q2 2026.
  • Sequoia Financial Advisors bought 124 Cytokinetics shares in Q2 2026, an estimated $8.9K.
  • Cytokinetics made up ﹤0.01% of Sequoia Financial Advisors's portfolio in Q2 2026, its #1671 holding.
  • Sequoia Financial Advisors first reported a position in Cytokinetics in Q4 2023 and has held it in 3 quarters since.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Sequoia Financial Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.